Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo

Neutralizing monoclonal antibodies (mAb) are a major therapeutic strategy for the treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The continuous emergence of new SARS-CoV-2 variants worldwide has increased the urgency for the development of new mAbs. In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qianran, Peng, Lu, Nie, Yanqiu, Shu, Yanni, Zhang, Huajun, Song, Zidan, Li, Yufeng, Hu, Hengrui, Li, Liushuai, Wang, Xi, Liu, Jia, Li, Jiang, Shi, Zhengli, Deng, Fei, Guo, Yu, Zhou, Yiwu, Yan, Bing, Hu, Zhihong, Wang, Manli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803610/
https://www.ncbi.nlm.nih.gov/pubmed/36596381
http://dx.doi.org/10.1016/j.virs.2022.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803610/
https://www.ncbi.nlm.nih.gov/pubmed/36596381
http://dx.doi.org/10.1016/j.virs.2022.12.007

Ejemplares similares